Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew: Hip sales grew just 1% in the U.S., while knee growth was up 4% in the first quarter, hindered by an industry-wide slowdown in reconstructive procedures. "What we expect from the [economic] environment and the headwind is that we don't expect it to get any easier any time soon," Smith & Nephew CEO David Illingworth cautioned during an April 30 earnings call. "And it could potentially soften a little bit more," he added. Global orthopedic sales were up 4% on a constant currency basis to $508 million. The firm's endoscopy business, which includes capital equipment, also was impacted by the economy, with sales falling 4% in the U.S. Global endoscopy sales were flat at $179 million. Consolidated net revenue was $865 million, down 5% on a reported basis, or up 4% at constant currency

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel